Maxime Verhoeven

84 Chapter 5 Table 1 Patients’ characteristics per individual randomized controlled trial. Early Established Trial U-Act-Early 9 n= 232 FUNCTION 7 n= 857 ACT-RAY 6 n= 417 Female, n (%) 161 (69) 677 (79) 345 (83) Age (years), mean (SD) 53.9 (12.4) 50.0 (13.0) 52.8 (12.1) BMI (kg/m²), mean (SD) 26.0 (4.4) 27.5 (6.2) 26.2 (5.1) Duration RA (years), median (IQR) 0.1 (0.0-0.1) 0.6 (0.1-1.1) 5.5 (2.3-11.4) Baseline DAS28, mean (SD) 5.1 (1.1) 6.7 (1.1) 6.3 (1.0) RF positive, n (%) 166 (72) 776 (91) - Baseline total SvdH score, median (IQR) 0 (0-1) 1.5 (0.5-5.5) 29 (17.5-50.5) Baseline Erosion SvdH score, median (IQR) 0 (0-0) 1 (0-3.5) 15.5 (10-24) Baseline JSN SvdH score, median (IQR) 0 (0-0) 0 (0-1.5) 13.5 (7-27) ∆ total SvdH score, median (IQR) 0 (0-1) 0 (0-0) 0 (0-0.5) ∆ Erosion SvdH score, median (IQR) 0 (0-1) 0 (0-0) 0 (0-0) ∆ JSN SvdH score, median (IQR) 0 (0-0) 0 (0-0) 0 (0-0.5) Initial treatment, n (%) - MTX monotherapy - TCZ+MTX 8mg/kg - TCZ+MTX 4mg/kg - TCZ-monotherapy 8mg/kg 74 (32) 78 (34) - 80 (34) 211 (25) 220 (25) 211 (25) 215 (25) - 215 (52) - 202 (48) GC-users, n (%) 0 (0) 429 (37) 212 (51) Baseline total SvdH score of 0, n (%) - MTX monotherapy - TCZ+MTX 8mg/kg - TCZ+MTX 4mg/kg - TCZ-monotherapy 8mg/kg 53 (72) 58 (74) - 57 (71) 55 (26) 55 (25) 44 (21) 54 (25) - 0 (0) - 0 (0) ∆ total SvdH score per initial treatment, median (IQR) - MTX monotherapy - TCZ+MTX 8mg/kg - TCZ+MTX 4mg/kg - TCZ-monotherapy 8mg/kg 0 (0-0) 0 (0-0) - 0 (0-1.5) 0 (0-0) 0 (0-0) 0 (0-0.5) 0 (0-0) - 0 (0-0.5) - 0 (0-0) ∆ total SvdH score of 0, n (%) - MTX monotherapy - TCZ+MTX 8mg/kg - TCZ+MTX 4mg/kg - TCZ-monotherapy 8mg/kg 39 (53) 61 (78) - 55 (68) 135 (64) 185 (84) 152 (72) 172 (80) - 129 (60) - 111 (55) n= number of patients; SD= standard deviation; BMI= body mass index; RA= rheumatoid arthritis; DAS28= disease activity score assessing 28 joints [range 0-9.4, higher is more active disease]; RF= rheumatoid factor; SvdH= Sharp van der Heijde [higher means more radiographic joint damage present]; JSN= joint space narrowing; GC= glucocorticoids; ∆= change from baseline to 2 years; MTX= methotrexate; TCZ= tocilizumab.